Cross-sectional Study for the Identification of Blood Biomarkers in Healthy Young and Old Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-12

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ageing is clearly the most important risk factor for AD and other dementias but, despite the amount of evidence supporting this fact, the exact mechanism that link ageing and AD is still unknown and, up to now, potential therapies for AD by targeting ageing have been poorly explored. This study aims to provide a better understanding of the link between ageing and AD by means of measuring in human blood those factors that have been found to be 'pro-youthful' (GDF-11, CSF2, TIMP-2, oxytocin) or 'pro-aging' (CCL2, CCL11, CCL19, Haptoglobine, B2-microglobuline) in experimental animal models, but have not been comprehensively studied in humans.

In this proof-of-concept study these blood factors in extreme groups of age, namely young adults (18-25 yo) and old adults (≥70 yo) will be measured and the hypothesis of whether the 'pro-youthful' and 'pro-ageing' blood factors change throughout age tested. In order to include a wider range of age, human umbilical cord blood and plasma from teenagers (which is already available from a previous study) will also be included.

The ultimate goal of this study is to select the more promising blood factors and obtain data on the effect size of the differences that may allow us in the future to design a larger study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.

NCT03851523

Alzheimer Disease Mild Cognitive Impairment Subjective Cognitive Decline

RECRUITING

Validation of Blood Biomarkers for Alzheimer's Disease

NCT05427448

Alzheimer Disease Mild Cognitive Impairment Dementia +1 more

COMPLETED NA

BarcelonaBeta Dementia Prevention Research Clinic: a Study on Risk Factors Disclosure

NCT03847038

Alzheimer Disease Dementia Mild Cognitive Impairment +1 more

COMPLETED NA

Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)

NCT00987090

Alzheimer's Disease

UNKNOWN NA

Clinical Application and Usability of Blood Biomarkers As Screening Tool in Alzheimer Disease: a Validation Study

NCT06699992

Cognitive Decline

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young adults group

Cognitively unimpaired 18-25 years old

No intervention

Intervention Type OTHER

No intervention

Old adults group

Cognitively unimpaired \>= 70 years old

No intervention

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women between 18 and 25 years (young adults group) or older than 70 for persons at the time of inclusion (old adults group).
2. Subjects with no subjective cognitive complaints.
3. Individuals interested in participating in the study who fully understand all the procedures that will be performed.
4. Explicit participant agreement to undergo all the study procedures, which encompass:

1. Collection of basic demographic data.
2. Collection of a blood sample.
5. Give informed consent and agree that no data resulting from the study (which is no clinically relevant) will be given to the participant

Exclusion Criteria

1. No signs of subjective cognitive impairment.
2. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol. Including: auditive and visual impairment, renal insufficiency under hemodialysis treatment, hepatic cirrhosis, chronic pneumopathy under oxygen therapy, solid organ transplantation, fibromyalgia, active oncologic disease under treatment (excluding localized tumours).
3. Any significant major psychiatric illness (following DSM-IV diagnosis manual) o diseases that interfere with cognitive function (including major depression disorder, bipolar disorder, schizophrenia).
4. Acquired brain injury: brain traumatic injury with parenchymal or extra-axial macroscopic injury, large vessel ischemic stroke or hemorrhagic stroke, brain tumors or other conditions that may cause acquired brain injury (brain radio- or chemotherapy).
5. Parkinson's disease, epilepsy under treatment and with frequent seizures (\>1 /month) in the last year, multiple sclerosis or any other neurodegenerative disease.
6. Researcher criteria: individuals that have any condition which, under researcher's view, could lead to difficulty complying with the protocol.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No